Bipolar disorder: From genes to behavior pathways

Journal of Clinical Investigation

Volumn 119, Issue 4, 2009, Pages 726-736

  Martinowich, Keri ^a   Schloesser, Robert J ^a   Manji, Husseini K ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; IMIPRAMINE; LITHIUM; TAMOXIFEN; VALPROIC ACID;

BEHAVIOR; BIPOLAR DISORDER; CADAVER; DEPRESSION; DRUG EFFECT; GENE; HUMAN; HUMAN GENETICS; MANIA; MOLECULAR BIOLOGY; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRESS; ANIMAL; BIOLOGICAL MODEL; BRAIN; DISEASE MODEL; GENETIC ENGINEERING; GENETICS; MOUSE; NERVE TRACT; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SIGNAL TRANSDUCTION;

ANIMALS; BEHAVIOR; BIPOLAR DISORDER; BRAIN; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; MICE; MODELS, NEUROLOGICAL; NEURAL PATHWAYS; SIGNAL TRANSDUCTION;

EID: 65249157014     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37703     Document Type: Review

References (138)

1. Belmaker, R.H. 2004. Bipolar disorder. N. Engl. J. Med. 351:476-486.
2. Kupfer, D.J. 2005. The increasing medical burden in bipolar disorder. JAMA. 293:2528-2530.
3. Akiskal, H.S., et al. 2000. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J. Affect. Disord. 59(Suppl. 1):S5-S30.
4. Wilkins, A.J., Shallice, T., and McCarthy, R. 1987. Frontal lesions and sustained attention. Neuropsychologia. 25:359-365.
5. Carlson, P.J., Singh, J.B., Zarate, C.A., Drevets, W.C., and Manji, H.K. 2006. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx. 3:22-41.
6. Blumberg, H.P., et al. 1999. Rostral and orbital prefrontal cortex dysfunction in the manic state of bipolar disorder. Am. J. Psychiatry. 156:1986-1988.
7. Woods, D.L., and Knight, R.T. 1986. Electrophysiologic evidence of increased distractibility after dorsolateral prefrontal lesions. Neurology. 36:212-216.
8. Brambilla, P., et al. 2001. Differential effects of age on brain gray matter in bipolar patients and healthy individuals. Neuropsychobiology. 43:242-247.
9. Schlaepfer, T.E., et al. 1994. Decreased regional cortical gray matter volume in schizophrenia. Am. J. Psychiatry. 151:842-848.
10. Zipursky, R.B., et al. 1997. Deficits in gray matter volume are present in schizophrenia but not bipolar disorder. Schizophr. Res. 26:85-92.
11. Nasrallah, H.A., McCalley-Whitters, M., and Jacoby, C.G. 1982. Cortical atrophy in schizophrenia and mania: a comparative CT study. J. Clin. Psychiatry. 43:439-441.
12. Pearlson, G.D., and Veroff, A.E. 1981. Computerised tomographic scan changes in manic-depressive illness. Lancet. 2:470.
13. Drevets, W.C., et al. 1997. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 386:824-827.
14. Brambilla, P., et al. 2002. Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. Neuropsychopharmacology. 27:792-799.
15. Frangou, S., Raymont, V., and Bettany, D. 2002. The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disord. 4:378-385.
16. Noga, J.T., Vladar, K., and Torrey, E.F. 2001. A volumetric magnetic resonance imaging study of monozygotic twins discordant for bipolar disorder. Psychiatry Res. 106:25-34.
17. Altshuler, L.L., et al. 1995. T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. Am. J. Psychiatry. 152:1139-1144.
18. Stoll, A.L., Renshaw, P.F., Yurgelen-Todd, D.A., and Cohen, B.M. 2000. Neuroimaging in bipolar disorder: what have we learned? Biol. Psychiatry. 48:505-517.
19. Ovbiagele, B., and Saver, J.L. 2006. Cerebral white matter hyperintensities on MRI: Current concepts and therapeutic implications. Cerebrovasc. Dis. 22:83-90.
20. Lyoo, I.K., Lee, H.K., Jung, J.H., Noam, G.G., and Renshaw, P.F. 2002. White matter hyperintensities on magnetic resonance imaging of the brain in children with psychiatric disorders. Compr. Psychiatry. 43:361-368.
21. Pillai, J.J., et al. 2002. Increased presence of white matter hyperintensities in adolescent patients with bipolar disorder. Psychiatry. Res. 114:51-56.
22. Lenox, R.H., Gould, T.D., and Manji, H.K. 2002. Endophenotypes in bipolar disorder. Am. J. Med. Genet. 114:391-406.
23. Moore, P.B., et al. 2001. Cerebral white matter lesions in bipolar affective disorder: relationship to outcome. Br. J. Psychiatry. 178:172-176.
24. Schloesser, R.J., Huang, J., Klein, P.S., and Manji, H.K. 2008. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 33:110-133.
25. Hamakawa, H., et al. 2004. Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin. Neurosci. 58:82-88.
26. Kato, T., et al. 1998. Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity. Eur. Arch. Psychiatry Clin. Neurosci. 248:301-306.
27. Hamakawa, H., Kato, T., Murashita, J., and Kato, N. 1998. Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 248:53-58.
28. Bertolino, A., et al. 2003. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biol. Psychiatry. 53:906-913.
29. Cecil, K.M., DelBello, M.P., Morey, R., and Strakowski, S.M. 2002. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord. 4:357-365.
30. Chang, K., et al. 2003. Decreased N-Acetylaspartate in children with familial bipolar disorder. Biol. Psychiatry. 53:1059-1065.
31. Diecken, R.F., Pegues, M.P., Anzalone, S., Feiwell, R., and Soher, B. 2003. Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. Am. J. Psychiatry. 160:873-882.
32. Winsberg, M.E., et al. 2000. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol. Psychiatry. 47:475-481.
33. Diecken, R.F., Fein, G., and Weiner, M.W. 1995. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am. J. Psychiatry. 152:915-918.
34. Kato, T., et al. 1995. Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phaseencoded 31P-MRS. Psychol. Med. 25:557-566.
35. Volz, H.P., et al. 1998. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur. Arch. Psychiatry Clin. Neurosci. 248:289-295.
36. Goodwin, F.K., and Jamison, K.R. 2007. Manicdepressive illness: bipolar disorders and recurrent depression. Oxford University Press. New York, New York, USA. 1288 pp.
37. Quiroz, J.A., Gray, N.A., Kato, T., and Manji, H.K. 2008. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 33:2551-2565.
38. Duman, R.S., and Monteggia, L.M. 2006. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry. 59:1116-1127.
39. Mattson, M.P. 2007. Mitochondrial regulation of neuronal plasticity. Neurochem. Res. 32:707-715.
40. Williams, J.M., Thompson, V.L., Mason-Parker, S.E., Abraham, W.C., and Tate, W.P. 1998. Synaptic activity-dependent modulation of mitochondrial gene expression in the rat hippocampus. Brain Res. Mol. Brain Res. 60:50-56.
41. Castillo, M., Kwock, L., Courvoisie, H., and Hooper, S.R. 2000. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR Am. J. Neuroradiol. 21:832-838.
42. Sanacora, G., et al. 2004. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry. 61:705-713.
43. Bielau, H., et al. 2005. Volume deficits of subcortical nuclei in mood disorders A postmortem study. Eur. Arch. Psychiatry Clin. Neurosci. 255:401-412.
44. Rajkowska, G. 2002. Cell pathology in bipolar disorder. Bipolar Disord. 4:105-116.
45. Cotter, D., et al. 2002. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cerebral Cortex. 12:386-394.
46. Liu, L., Schulz, S.C., Lee, S., Reutiman, T.J., and Fatemi, S.H. 2007. Hippocampal CA1 pyramidal cell size is reduced in bipolar disorder. Cell. Mol. Neurobiol. 27:351-358.
47. Cotter, D., et al. 2002. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol. Psychiatry. 51:377-386.
48. Pantazopoulos, H., Lange, N., Baldessarini, R.J., and Berretta, S. 2007. Parvalbumin neurons in the entorhinal cortex of subjects diagnosed with bipolar disorder or schizophrenia. Biol. Psychiatry. 61:640-652.
49. Konradi, C., et al. 2004. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry. 61:300-308.
50. Ongur, D., Drevets, W.C., and Price, J.L. 1998. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. U. S. A. 95:13290-13295.
51. Rajkowska, G. 2000. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry. 48:766-777.
52. Rajkowska, G., Halaris, A., and Selemon, L.D. 2001. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry. 49:741-752.
53. Johnston-Wilson, N.L., et al. 2000. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatry. 5:142-149.
54. Uranova, N.A., Vostrikov, V.M., Orlovskaya, D.D., and Rachmanova, V.I. 2004. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 67:269-275.
55. Strittmatter, S.M. 1992. GAP-43 as a modulator of G protein transduction in the growth cone. Perspect. Dev. Neurobiol. 1:13-19.
56. Eastwood, S.L., and Harrison, P.J. 2001. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res. Bull. 55:569-578.
57. Tian, S.Y., Wang, J.F., Bezchlibnyk, Y.B., and Young, L.T. 2007. Immunoreactivity of 43 kDa growthassociated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia. Neurosci. Lett. 411:123-127.
58. Hilfiker, S., et al. 1999. Synapsins as regulators of neurotransmitter release. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:269-279.
59. Vawter, M.P., et al. 2002. Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia. Mol. Psychiatry. 7:571-578.
60. Scarr, E., Gray, L., Keriakous, D., Robinson, P.J., and Dean, B. 2006. Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. Bipolar Disord. 8:133-143.
61. Beasley, C.L., et al. 2005. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord. 7:449-455.
62. Eastwood, S.L., and Harrison, P.J. 2007. Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder. Neuropsychopharmacology. 33:933-945.
63. Bertelsen, A., Harvald, B., and Hauge, M. 1977. A Danish twin study of manic-depressive disorders. Br. J. Psychiatry. 130:330-351.
64. Cardno, A.G., et al. 1999. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch. Gen. Psychiatry. 56:162-168.
65. Mendlewicz, J., and Rainer, J.D. 1977. Adoption study supporting genetic transmission in manicdepressive illness. Nature. 268:327-329.
66. Hayden, E.P., and Nurnberger, J.I., Jr. 2006. Molecular genetics of bipolar disorder. Genes Brain Behav. 5:85-95.
67. Baum, A.E., et al. 2008. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry. 13:197-207.
68. Newberg, A.R., Catapano, L.A., Zarate, C.A., and Manji, H.K. 2008. Neurobiology of bipolar disorder. Expert Rev. Neurother. 8:93-110.
69. Kato, T. 2007. Molecular genetics of bipolar disorder and depression. Psychiatry Clin. Neurosci. 61:3-19.
70. Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447:661-678.
71. Sklar, P., et al. 2008. Whole-genome association study of bipolar disorder. Mol. Psychiatry. 13:558-569.
72. Ferreira, M.A., et al. 2008. Collaborative genomewide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40:1056-1058.
73. Nestler, E.J., et al. 2002. Preclinical models: status of basic research in depression. Biol. Psychiatry. 52:503-528.
74. Flint, J., and Shifman, S. 2008. Animal models of psychiatric disease. Curr. Opin. Genet. Dev. 18:235-240.
75. Seligman, M.E., and Maier, S.F. 1967. Failure to escape traumatic shock. J. Exp. Psychol. 74:1-9.
76. Porsolt, R.D. 2000. Animal models of depression: utility for transgenic research. Rev. Neurosci. 11:53-58.
77. Einat, H., Manji, H.K., and Belmaker, R.H. 2003. New approaches to modeling bipolar disorder. Psychopharmacol. Bull. 37:47-63.
78. Gessa, G.L., Pani, L., Fadda, P., and Fratta, W. 1995. Sleep deprivation in the rat: an animal model of mania. Eur. Neuropsychopharmacol. 5(Suppl.):89-93.
79. Gessa, G.L., Pani, L., Serra, G., and Fratta, W. 1995. Animal models of mania. Adv. Biochem. Psychopharmacol. 49:43-66.
80. Smith, M.A., Makino, S., Kvetnansky, R., and Post, R.M. 1995. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J. Neurosci. 15:1768-1777.
81. Morinobu, S., Nibuya, M., and Duman, R.S. 1995. Chronic antidepressant treatment down-regulates the induction of c-fos mRNA in response to acute stress in rat frontal cortex. Neuropsychopharmacology. 12:221-228.
82. Shirayama, Y., Chen, A.C., Nakagawa, S., Russell, D.S., and Duman, R.S. 2002. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22:3251-3261.
83. Berton, O., et al. 2006. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 311:864-868.
84. Monteggia, L.M., et al. 2004. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. U. S. A. 101:10827-10832.
85. Santarelli, L., et al. 2003. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 301:805-809.
86. Schmidt, H.D., and Duman, R.S. 2007. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav. Pharmacol. 18:391-418.
87. Roybal, K., et al. 2007. Mania-like behavior induced by disruption of CLOCK. Proc. Natl. Acad. Sci. U. S. A. 104:6406-6411.
88. Shaltiel, G., et al. 2008. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol. Psychiatry. 13:858-872.
89. Maeng, S., et al. 2008. BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc. Natl. Acad. Sci. U. S. A. 105:8766-8771.
90. Zhou, R., et al. 2005. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J. Neurosci. 25:4493-4502.
91. Bachmann, R.F., Schloesser, R.J., Gould, T.D., and Manji, H.K. 2005. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol. Neurobiol. 32:173-202.
92. Zarate, C.A., Jr., and Manji, H.K. 2008. Bipolar disorder: candidate drug targets. Mt. Sinai J. Med. 75:226-247.
93. Davies, S.P., Reddy, H., Caivano, M., and Cohen, P. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:95-105.
94. Ryves, W.J., and Harwood, A.J. 2001. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Comm. 280:720-725.
95. Gould, T.D., and Manji, H.K. 2005. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 30:1223-1237.
96. Gurvich, N., and Klein, P.S. 2002. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96:45-66.
97. Li, X., Bijur, G.N., and Jope, R.S. 2002. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4:137-144.
98. Berridge, M.J., Downes, C.P., and Hanley, M.R. 1989. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 59:411-419.
99. Hallcher, L.M., and Sherman, W.R. 1980. The effects of lithium ion and other agents on the activity of myo- inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255:10896-10901.
100. Dixon, J.F., Los, G.V., and Hokin, L.E. 1994. Lithium stimulates glutamate "release" and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proc. Natl. Acad. Sci. U. S. A. 91:8358-8362.
101. Berry, G.T., Buccafusca, R., Greer, J.J., and Eccleston, E. 2004. Phosphoinositide deficiency due to inositol depletion is not a mechanism of lithium action in brain. Mol. Genet. Metab. 82:87-92.
102. Zarate, C.A., et al. 2007. Efficacy of a protein kinase C Inhibitor (Tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 9:561-570.
103. Bebchuk, J.M., et al. 2000. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry. 57:95-97.
104. Lucas, F.R., Goold, R.G., Gordon-Weeks, P.R., and Salinas, P.C. 1998. Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J. Cell Sci. 111:1351-1361.
105. Williams, R.S., Cheng, L., Mudge, A.W., and Harwood, A.J. 2002. A common mechanism of action for three mood-stabilizing drugs. Nature. 417:292-295.
106. Hall, A.C., Lucas, F.R., and Salinas, P.C. 2000. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell. 100:525-535.
107. Salinas, P.C. 1999. Wnt factors in axonal remodelling and synaptogenesis. Biochem. Soc. Symp. 65:101-109.
108. Chen, G., Rajkowska, G., Du, F., Seraji-Bozorgzad, N., and Manji, H.K. 2000. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75:1729-1734.
109. Burden, S.J. 2000. Wnts as retrograde signals for axon and growth cone differentiation. Cell. 100:495-497.
110. Lie, D.C., et al. 2005. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 437:1370-1375.
111. Chalecka-Franaszek, E., and Chuang, D.M. 1999. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 96:8745-8750.
112. Zhang, F., Phiel, C.J., Spece, L., Gurvich, N., and Klein, P.S. 2003. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. 278:33067-33077.
113. Gould, T.D., Einat, H., Bhat, R., and Manji, H.K. 2004. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 7:387-390.
114. Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C.G., and Eldar-Finkelman, H. 2004. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on betacatenin in mouse hippocampus. Biol. Psychiatry. 55:781-784.
115. Chen, G., et al. 1999. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72:879-882.
116. Chuang, D.M. 2004. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit. Rev. Neurobiol. 16:83-90.
117. Bruckheimer, E.M., Cho, S.H., Sarkiss, M., Hermann, J., and McDonnell, T.J. 1998. The Bcl-2 gene family and apoptosis. Adv. Biochem. Eng. Biotechnol. 62:75-105.
118. Shaltiel, G., Chen, G., and Manji, H.K. 2007. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr. Opin. Pharmacol. 7:22-26.
119. Chuang, D.M., and Manji, H.K. 2007. In search of the holy grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol. Psychiatry. 62:4-6.
120. Moore, G.J., et al. 2000. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol. Psychiatry. 48:1-8.
121. Moore, G.J., Bebchuk, J.M., Wilds, I.B., Chen, G., and Manji, H.K. 2000. Lithium-induced increase in human brain grey matter. Lancet. 356:1241-1242.
122. Tsankova, N., Renthal, W., Kumar, A., and Nestler, E.J. 2007. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8:355-367.
123. Weaver, I.C., et al. 2004. Epigenetic programming by maternal behavior. Nat. Neurosci. 7:847-854.
124. Weaver, I.C., Meaney, M.J., and Szyf, M. 2006. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc. Natl. Acad. Sci. U. S. A. 103:3480-3485.
125. Wei, Q., et al. 2004. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc. Natl. Acad. Sci. U. S. A. 101:11851-11856.
126. Wellman, C.L., et al. 2007. Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J. Neurosci. 27:684-691.
127. Adamec, R., Burton, P., Blundell, J., Murphy, D.L., and Holmes, A. 2006. Vulnerability to mild predator stress in serotonin transporter knockout mice. Behav. Brain Res. 170:126-140.
128. Homes, A., Murphy, D.L., and Crawley, J.N. 2002. Reduced aggression in mice lacking the serotonin transporter. Psychopharmacology. (Berl.) 161:160-167.
129. Chourbaji, S., et al. 2008. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J. 22:3129-3134.
130. Einat, H., Yuan, P., and Maji, H.K. 2005. Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav. Brain Res. 165:172-180.
131. Spittaels, K., et al. 2000. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275:41340-41349.
132. Koo, J.W., and Duman, R.S. 2008. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. U. S. A. 105:751-756.
133. Saarelainen, T., et al. 2003. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23:349-357.
134. O'Brien, W.T., et al. 2004. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24:6791-6798.
135. Gould, T.D., et al. 2007. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology. 32:2173-2183.
136. Chourbaji, S., et al. 2006. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol. Dis. 23:587-594.
137. Gur, T.L., et al. 2007. cAMP response elementbinding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J. Neurosci. 27:7860-7868.
138. Koponen, E., et al. 2005. Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines. Cell. Mol. Neurobiol. 25:973-980.